Unknown

Dataset Information

0

A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct.


ABSTRACT: MASTL (microtubule-associated serine/threonine kinase-like), more commonly known as Greatwall (GWL), has been proposed as a novel cancer therapy target. GWL plays a crucial role in mitotic progression, via its known substrates ENSA/ARPP19, which when phosphorylated inactivate PP2A/B55 phosphatase. When over-expressed in breast cancer, GWL induces oncogenic properties such as transformation and invasiveness. Conversely, down-regulation of GWL selectively sensitises tumour cells to chemotherapy. Here we describe the first structure of the GWL minimal kinase domain and development of a small-molecule inhibitor GKI-1 (Greatwall Kinase Inhibitor-1). In vitro, GKI-1 inhibits full-length human GWL, and shows cellular efficacy. Treatment of HeLa cells with GKI-1 reduces ENSA/ARPP19 phosphorylation levels, such that they are comparable to those obtained by siRNA depletion of GWL; resulting in a decrease in mitotic events, mitotic arrest/cell death and cytokinesis failure. Furthermore, GKI-1 will be a useful starting point for the development of more potent and selective GWL inhibitors.

SUBMITTER: Ocasio CA 

PROVIDER: S-EPMC5342071 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct.

Ocasio Cory A CA   Rajasekaran Mohan B MB   Walker Sarah S   Le Grand Darren D   Spencer John J   Pearl Frances M G FM   Ward Simon E SE   Savic Velibor V   Pearl Laurence H LH   Hochegger Helfrid H   Oliver Antony W AW  

Oncotarget 20161101 44


MASTL (microtubule-associated serine/threonine kinase-like), more commonly known as Greatwall (GWL), has been proposed as a novel cancer therapy target. GWL plays a crucial role in mitotic progression, via its known substrates ENSA/ARPP19, which when phosphorylated inactivate PP2A/B55 phosphatase. When over-expressed in breast cancer, GWL induces oncogenic properties such as transformation and invasiveness. Conversely, down-regulation of GWL selectively sensitises tumour cells to chemotherapy. H  ...[more]

Similar Datasets

2013-07-17 | GSE48925 | GEO
2013-07-17 | E-GEOD-48925 | biostudies-arrayexpress
| S-ECPF-GEOD-48925 | biostudies-other
| S-EPMC3128519 | biostudies-literature
| S-EPMC3459938 | biostudies-literature
| S-EPMC5612104 | biostudies-literature
| S-EPMC4612739 | biostudies-literature
| S-EPMC5025047 | biostudies-literature
| S-EPMC2291418 | biostudies-literature
| S-EPMC6668337 | biostudies-literature